 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||||| adezunap (AP707) / CannaXan, Apurano Pharma
Enrollment open: Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain (clinicaltrials.gov) - Jan 31, 2024
P3, N=558, Recruiting, Sponsor: Apurano Pharmaceuticals GmbH
Not yet recruiting --> Recruiting
- |||||| adezunap (AP707) / CannaXan, Apurano Pharma
Enrollment open: Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy (clinicaltrials.gov) - Jan 31, 2024
P3, N=558, Recruiting, Sponsor: Apurano Pharmaceuticals GmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| adezunap (AP707) / CannaXan, Apurano Pharma
Enrollment open: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy (clinicaltrials.gov) - Jan 31, 2024
P3, N=558, Recruiting, Sponsor: Apurano Pharmaceuticals GmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| adezunap (AP707) / CannaXan, Apurano Pharma
Enrollment open: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain (clinicaltrials.gov) - Jan 31, 2024
P3, N=558, Recruiting, Sponsor: Apurano Pharmaceuticals GmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| adezunap (AP707) / CannaXan, Apurano Pharma
Enrollment open: Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy (clinicaltrials.gov) - Jan 31, 2024
P3, N=558, Recruiting, Sponsor: Apurano Pharmaceuticals GmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| adezunap (AP707) / CannaXan, Apurano Pharma
Enrollment open: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis (clinicaltrials.gov) - Jan 31, 2024
P3, N=558, Recruiting, Sponsor: Apurano Pharmaceuticals GmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| adezunap (AP707) / CannaXan, Apurano Pharma
Enrollment open: Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis (clinicaltrials.gov) - Jan 31, 2024
P3, N=558, Recruiting, Sponsor: Apurano Pharmaceuticals GmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| adezunap (AP707) / CannaXan, Apurano Pharma
Enrollment open: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy (clinicaltrials.gov) - Jan 31, 2024
P3, N=558, Recruiting, Sponsor: Apurano Pharmaceuticals GmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | adezunap (AP707) / CannaXan, Apurano Pharma
New P3 trial: Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy (clinicaltrials.gov) - Oct 9, 2023
P3, N=558, Not yet recruiting, Sponsor: Apurano Pharmaceuticals GmbH
- | adezunap (AP707) / CannaXan, Apurano Pharma
New P3 trial: Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis (clinicaltrials.gov) - Oct 9, 2023
P3, N=558, Not yet recruiting, Sponsor: Apurano Pharmaceuticals GmbH
- | adezunap (AP707) / CannaXan, Apurano Pharma
New P3 trial: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain (clinicaltrials.gov) - Oct 9, 2023
P3, N=558, Not yet recruiting, Sponsor: Apurano Pharmaceuticals GmbH
- | adezunap (AP707) / CannaXan, Apurano Pharma
New P3 trial: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy (clinicaltrials.gov) - Oct 9, 2023
P3, N=558, Not yet recruiting, Sponsor: Apurano Pharmaceuticals GmbH
- | adezunap (AP707) / CannaXan, Apurano Pharma
New P3 trial: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy (clinicaltrials.gov) - Oct 9, 2023
P3, N=558, Not yet recruiting, Sponsor: Apurano Pharmaceuticals GmbH
- | adezunap (AP707) / CannaXan, Apurano Pharma
New P3 trial: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis (clinicaltrials.gov) - Oct 9, 2023
P3, N=558, Not yet recruiting, Sponsor: Apurano Pharmaceuticals GmbH
- | adezunap (AP707) / CannaXan, Apurano Pharma
New P3 trial: Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain (clinicaltrials.gov) - Oct 9, 2023
P3, N=558, Not yet recruiting, Sponsor: Apurano Pharmaceuticals GmbH
- | adezunap (AP707) / CannaXan, Apurano Pharma
New P3 trial: Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy (clinicaltrials.gov) - Oct 9, 2023
P3, N=558, Not yet recruiting, Sponsor: Apurano Pharmaceuticals GmbH
- || adezunap (AP707) / CannaXan, Apurano Pharma
Trial completion, Enrollment change: Clinical Trial on Pharmacokinetics and Tolerability of AP707 (clinicaltrials.gov) - Jul 27, 2022
P1, N=12, Completed, Sponsor: CannaXan GmbH
Not yet recruiting --> Recruiting Recruiting --> Completed | N=20 --> 12
- || adezunap (AP707) / CannaXan, Apurano Pharma
New P1 trial: Clinical Trial on Pharmacokinetics and Tolerability of AP707 (clinicaltrials.gov) - Mar 3, 2022
P1, N=20, Recruiting, Sponsor: CannaXan GmbH